iSpecimen Inc. has successfully raised $400,000 through a private placement of its Series D Convertible Preferred Stock. This funding will be used for working capital and general corporate purposes, marking a strategic step for the company as it continues to navigate the competitive landscape of the commercial physical and biological research industry.

On November 6, 2026, iSpecimen entered into a Securities Purchase Agreement with accredited investors for the sale of 500 shares of Series D Preferred Stock at a price of $800 per share. The closing of this offering occurred on the same day, demonstrating the company's ability to attract investment in a challenging market.

The Series D Preferred Stock features a stated value of $1,000 per share and is convertible into common stock at the holder's option. The conversion price is set at the greater of 85% of the closing price of the common stock on the trading day before conversion or a floor price of $0.1616. This structure provides investors with a potential upside while ensuring iSpecimen can access necessary funds.

In addition to the Securities Purchase Agreement, iSpecimen also entered into a Placement Agency Agreement with E.F. Hutton & Co., which acted as the exclusive placement agent for the offering. As part of this agreement, iSpecimen will pay a cash fee of 4% of the gross proceeds, along with a non-accountable expense allowance of 1%.

The company has also established lock-up agreements with its directors and executive officers, preventing them from selling or disposing of any securities for 90 days following the closing of the offering. This move is designed to stabilize the stock and build investor confidence in the wake of this capital raise.

iSpecimen's recent actions highlight its commitment to strengthening its financial position amidst evolving market conditions. As the commercial physical and biological research sector continues to grow, other companies may look to similar funding strategies to enhance their operational capabilities.

Details about the rights and preferences of the Series D Preferred Stock are outlined in the Certificate of Designations filed with the Secretary of State of Delaware. The company has committed to filing a registration statement covering the resale of common stock issuable upon conversion of the Series D Preferred Stock within 30 days of the offering's closing.

This capital raise is a significant development for iSpecimen, as it seeks to leverage the funds to support its ongoing operations and potentially expand its market presence. The company’s ability to secure this funding may influence how it competes within the commercial physical and biological research industry, where innovation and operational efficiency are critical.

Looking ahead, iSpecimen's management will likely focus on utilizing the raised capital effectively to drive growth and enhance shareholder value. The filing does not specify what happens next, but the company’s proactive approach indicates a focus on strategic initiatives in the near future.